Striatal Mechanisms of Levodopa-Induced Dyskinesia

左旋多巴引起的运动障碍的纹状体机制

基本信息

项目摘要

Project Summary Levodopa-induced dyskinesia (LID) commonly develops during long-term treatment of Parkinson's Disease, affecting most patients after 5-10 years of treatment. The abnormal involuntary movements eventually limit the levodopa dose, and often patients require deep brain stimulation (DBS). The neural mechanisms of LID are not fully understood, but the leading hypothesis is that levodopa triggers aberrant activity in the input nucleus of the basal ganglia, the striatum. Even in the advanced stages of disease, however, levodopa continues to have both therapeutic and pathological effects, promoting normal movement and abnormal involuntary movements. This clinical observation led us to hypothesize that within the striatum, distinct populations of neurons correlate with dyskinetic versus prokinetic (therapeutic) effects of levodopa. Our pilot studies indicate that a substantial fraction of striatal neurons show strong correlations in their activity with either increased normal movement, or dyskinesia, and few neurons correlate with both responses. By understanding the intrinsic and synaptic properties that distinguish these two groups of striatal neurons, subsequent drug development might be able to selectively target movement neurons, relieving motor symptoms of Parkinson's Disease, without affecting dyskinetic neurons and avoiding dyskinesia. Using a combination of awake-behaving single-unit recordings, optogenetics, and ex vivo slice recordings in a mouse model of LID, this proposal aims to (1) characterize striatal direct pathway neuronal responses to levodopa, including identifying units whose firing correlates with dyskinesia, (2) determine whether these neurons cause dyskinesia, and (3) identify the underlying cellular mechanisms (alterations in intrinsic excitability and/or excitatory inputs) that distinguish them. To test the causal role of dyskinesia-correlated striatal units in dyskinesia, we will use the novel transgenic tool, Targeted Recombination in Active Populations (TRAP), which allows capture and subsequent manipulation of previously activated neurons. These studies will provide the first detailed look at whether levodopa triggers therapeutic and dyskinetic effects through two different striatal effector populations, and begin to dissect the underlying cellular and synaptic mechanisms. !
项目摘要 左旋多巴诱导的运动障碍(LID)通常在帕金森病的长期治疗期间发展, 大多数患者在治疗5-10年后仍会受到影响。不正常的不自主运动最终限制了 左旋多巴剂量,并且通常患者需要深部脑刺激(DBS)。LID的神经机制不是 完全理解,但主要的假设是左旋多巴触发输入核的异常活动, 基底神经节纹状体然而,即使在疾病的晚期,左旋多巴仍然具有 治疗和病理作用,促进正常运动和异常不自主运动。 这一临床观察使我们假设,在纹状体内,不同的神经元群体 与运动障碍对比左旋多巴的促运动(治疗)作用。我们的初步研究表明, 纹状体神经元的一部分在它们的活动中显示出与增加的正常运动或 运动障碍,很少有神经元与这两种反应相关。通过了解内在的和突触的 区分这两组纹状体神经元的特性,随后的药物开发可能能够 选择性靶向运动神经元,缓解帕金森病的运动症状,而不影响 运动障碍神经元和避免运动障碍。使用唤醒行为单一单元记录的组合, 光遗传学和LID小鼠模型中的离体切片记录,该提议旨在(1)表征 纹状体直接通路神经元对左旋多巴的反应,包括识别其放电与 运动障碍,(2)确定这些神经元是否引起运动障碍,以及(3)识别潜在的细胞 机制(内在兴奋性和/或兴奋性输入的改变)区分它们。测试 运动障碍相关的纹状体单位在运动障碍中的因果作用,我们将使用新的转基因工具,靶向 活动人群中的捕获(TRAP),允许捕获和随后操纵先前的 激活的神经元这些研究将提供第一个详细的观察左旋多巴是否触发治疗性 和运动障碍的影响,通过两个不同的纹状体效应人群,并开始解剖的基础 细胞和突触机制。 !

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Alexandra Nelson其他文献

Alexandra Nelson的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Alexandra Nelson', 18)}}的其他基金

Striatal Microcircuit Mechanisms of Tardive Dyskinesia
迟发性运动障碍的纹状体微电路机制
  • 批准号:
    10634474
  • 财政年份:
    2023
  • 资助金额:
    $ 28.26万
  • 项目类别:
Landis Award
兰迪斯奖
  • 批准号:
    10532481
  • 财政年份:
    2018
  • 资助金额:
    $ 28.26万
  • 项目类别:
Striatal Mechanisms of Levodopa-Induced Dyskinesia
左旋多巴引起的运动障碍的纹状体机制
  • 批准号:
    10161518
  • 财政年份:
    2018
  • 资助金额:
    $ 28.26万
  • 项目类别:
Striatal Mechanisms of Levodopa-Induced Dyskinesia
左旋多巴引起的运动障碍的纹状体机制
  • 批准号:
    10181085
  • 财政年份:
    2018
  • 资助金额:
    $ 28.26万
  • 项目类别:
Striatal Mechanisms of Dyskinesia and Impulse Control in Parkinson’s Disease
帕金森病运动障碍和冲动控制的纹状体机制
  • 批准号:
    10735816
  • 财政年份:
    2018
  • 资助金额:
    $ 28.26万
  • 项目类别:
Striatal Mechanisms of Levodopa-Induced Dyskinesia
左旋多巴引起的运动障碍的纹状体机制
  • 批准号:
    10408107
  • 财政年份:
    2018
  • 资助金额:
    $ 28.26万
  • 项目类别:
Optogenetic dissection of striatal circuits in a mouse model of human dystonia
人类肌张力障碍小鼠模型纹状体回路的光遗传学解剖
  • 批准号:
    8924030
  • 财政年份:
    2014
  • 资助金额:
    $ 28.26万
  • 项目类别:
Optogenetic dissection of striatal circuits in a mouse model of human dystonia
人类肌张力障碍小鼠模型纹状体回路的光遗传学解剖
  • 批准号:
    9114179
  • 财政年份:
    2014
  • 资助金额:
    $ 28.26万
  • 项目类别:
Optogenetic dissection of striatal circuits in a mouse model of human dystonia
人类肌张力障碍小鼠模型纹状体回路的光遗传学解剖
  • 批准号:
    8535857
  • 财政年份:
    2012
  • 资助金额:
    $ 28.26万
  • 项目类别:
Optogenetic dissection of striatal circuits in a mouse model of human dystonia
人类肌张力障碍小鼠模型纹状体回路的光遗传学解剖
  • 批准号:
    8425906
  • 财政年份:
    2012
  • 资助金额:
    $ 28.26万
  • 项目类别:

相似海外基金

RII Track-4:NSF: From the Ground Up to the Air Above Coastal Dunes: How Groundwater and Evaporation Affect the Mechanism of Wind Erosion
RII Track-4:NSF:从地面到沿海沙丘上方的空气:地下水和蒸发如何影响风蚀机制
  • 批准号:
    2327346
  • 财政年份:
    2024
  • 资助金额:
    $ 28.26万
  • 项目类别:
    Standard Grant
BRC-BIO: Establishing Astrangia poculata as a study system to understand how multi-partner symbiotic interactions affect pathogen response in cnidarians
BRC-BIO:建立 Astrangia poculata 作为研究系统,以了解多伙伴共生相互作用如何影响刺胞动物的病原体反应
  • 批准号:
    2312555
  • 财政年份:
    2024
  • 资助金额:
    $ 28.26万
  • 项目类别:
    Standard Grant
How Does Particle Material Properties Insoluble and Partially Soluble Affect Sensory Perception Of Fat based Products
不溶性和部分可溶的颗粒材料特性如何影响脂肪基产品的感官知觉
  • 批准号:
    BB/Z514391/1
  • 财政年份:
    2024
  • 资助金额:
    $ 28.26万
  • 项目类别:
    Training Grant
Graduating in Austerity: Do Welfare Cuts Affect the Career Path of University Students?
紧缩毕业:福利削减会影响大学生的职业道路吗?
  • 批准号:
    ES/Z502595/1
  • 财政年份:
    2024
  • 资助金额:
    $ 28.26万
  • 项目类别:
    Fellowship
感性個人差指標 Affect-X の構築とビスポークAIサービスの基盤確立
建立个人敏感度指数 Affect-X 并为定制人工智能服务奠定基础
  • 批准号:
    23K24936
  • 财政年份:
    2024
  • 资助金额:
    $ 28.26万
  • 项目类别:
    Grant-in-Aid for Scientific Research (B)
Insecure lives and the policy disconnect: How multiple insecurities affect Levelling Up and what joined-up policy can do to help
不安全的生活和政策脱节:多种不安全因素如何影响升级以及联合政策可以提供哪些帮助
  • 批准号:
    ES/Z000149/1
  • 财政年份:
    2024
  • 资助金额:
    $ 28.26万
  • 项目类别:
    Research Grant
How does metal binding affect the function of proteins targeted by a devastating pathogen of cereal crops?
金属结合如何影响谷类作物毁灭性病原体靶向的蛋白质的功能?
  • 批准号:
    2901648
  • 财政年份:
    2024
  • 资助金额:
    $ 28.26万
  • 项目类别:
    Studentship
ERI: Developing a Trust-supporting Design Framework with Affect for Human-AI Collaboration
ERI:开发一个支持信任的设计框架,影响人类与人工智能的协作
  • 批准号:
    2301846
  • 财政年份:
    2023
  • 资助金额:
    $ 28.26万
  • 项目类别:
    Standard Grant
Investigating how double-negative T cells affect anti-leukemic and GvHD-inducing activities of conventional T cells
研究双阴性 T 细胞如何影响传统 T 细胞的抗白血病和 GvHD 诱导活性
  • 批准号:
    488039
  • 财政年份:
    2023
  • 资助金额:
    $ 28.26万
  • 项目类别:
    Operating Grants
How motor impairments due to neurodegenerative diseases affect masticatory movements
神经退行性疾病引起的运动障碍如何影响咀嚼运动
  • 批准号:
    23K16076
  • 财政年份:
    2023
  • 资助金额:
    $ 28.26万
  • 项目类别:
    Grant-in-Aid for Early-Career Scientists
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了